

AMARIN'S REFINED STRATEGY

INVESTOR PRESENTATION

JUNE 24, 2025



 AMARIN

Forward-Looking Statements & Disclaimer

This presentation contains forward-looking statements, such as those relating to the commercial potential of VASCEPA®(VAZKEPA® in Europe), clinical and regulatory efforts and timelines, potential regulatory and pricing approvals, generic product launches, research and development, intellectual property and litigation matters, and other statements and beliefs that are forward-looking in nature and depend upon or refer to future events or conditions, including certain financial initiatives, metrics, guidance, and other statements.

These statements involve known and unknown risks, uncertainties and other factors that can cause actual results to differ materially. Investors should not place undue reliance on forward-looking statements, which speak only as of the presentation date of this presentation. Please refer to the “Risk Factors” section in Amarin’s most recent Forms 10-K and 10-Q filed with the SEC and cautionary statements outlined in recent press releases for more complete descriptions of risks in an investment in Amarin.

THIS PRESENTATION IS INTENDED FOR COMMUNICATION WITH INVESTORS AND NOT FOR DRUG PROMOTION.

AMARIN, VASCEPA, VAZKEPA and REDUCE-IT are trademarks of Amarin Pharmaceuticals Ireland Limited. VAZKEPA is a registered trademark in Europe and other countries and regions and is pending registration in the United States.



CORPORATE ACTIONS TO EXPAND VAZKEPA PATIENT USE IN EUROPE AND INCREASE SHAREHOLDER VALUE

RECORDATI EXCLUSIVE LICENSE & SUPPLY AGREEMENT TO COMMERCIALIZE VAZKEPA IN EUROPE

New strategic pathway to further maximize VAZKEPA in Europe

RIGHT-SIZING ORGANIZATION TO DRIVE EFFICIENT REVENUE GLOBALLY & ACCELERATE POSITIVE CASH FLOW

Global restructuring expected to generate ~\$70M in cost savings over next 12 months

EXPLORING OPTIONS TO MAXIMIZE SHAREHOLDER VALUE

Continue to explore potential additional strategic opportunities to create shareholder value

Significant steps being taken to accelerate path to positive cash flow and strengthen strategic position for the future

UNDERPINNED BY VASCEPA/VAZKEPA GLOBAL GROWTH OPPORTUNITY

Large global burden of disease and need for CV risk reduction

60M patients with CVD in Europe

Powerful REDUCE-IT data; Proven efficacy and safety

Broad global KOL and scientific guideline support; 50+ endorsements from leading medical societies

Unique and complementary to current therapies

CVRR Indication regulatory approvals in 49 global markets



MAXIMIZING VAZKEPA OPPORTUNITY IN EUROPE WITH RECORDATI AGREEMENT

LEVERAGING RECORDATI'S PROVEN EXPERTISE TO ACCELERATE DEPTH AND REACH OF VAZKEPA FOR PATIENTS



Multi-billion-dollar global company with significant European operations

Long and extensive **cardiovascular disease heritage**

Product portfolio addresses range of diseases, including cholesterol, hypertension, heart failure and other conditions

Established operations to support and grow VAZKEPA across Europe

TRANSACTION IMMEDIATELY STRENGTHENS FINANCIAL POSITION IN NEAR- AND LONG-TERM

\$25M
upfront cash

Up to \$150M
milestone payments contingent upon Recordati achieving predefined commercial net sales levels

Supply-based revenues, including royalties
for supply of product to Recordati





VAZKEPA IN EUROPE: RECENT PROGRESS & LONG IP RUNWAY CREATE OPPORTUNITY FOR SIGNIFICANT GROWTH BY RECORDATI

RECENT PROGRESS PROVIDES FAVORABLE MARKET DYNAMICS TO ACCELERATE GROWTH

- Exclusive long-term license and supply agreement to commercialize VAZKEPA across 59 countries, focused in Europe
- Partner with strong cardiovascular expertise & established commercial and medical presence across all European markets can amplify progress & accelerate uptake

VAZKEPA PRICING & REIMBURSEMENT / COMMERCIALIZATION PROGRESS

- Pricing & Reimbursement secured and access opened to **over half** of eligible patient population in Western Europe
- Commercially available in **10** European and Central and Eastern Europe markets
- Unlocked regional access accounting for **91%** of eligible patient population in Italy shortly after national reimbursement; country now ready for full commercial launch
- Strong medical advocacy and support across Europe; inclusion of VAZKEPA in multiple European and national guidelines & protocols
- Revised potential strategies for resubmission in France and Germany identified



ADVANCING AMARIN'S STRATEGY



CONTINUED COST SAVINGS ACCELERATES PATH TO POSITIVE CASH FLOW

~\$70M


additional cost savings over next 12 months

Recordati agreement and global restructuring strengthens capital structure:

- Stable cash position since 2022 with no debt
- Cost effective revenue generation from US, Europe and Rest of World markets
- Continued expense optimization while driving growth expected to further bolster cash position
- Inventory draw-down continues and supply commitments will be in-line with revenue growth in early-stage markets

YoY Annual Operating Expense Savings

\$ in millions



1. Existing Savings based on annualized Q1 2025 operating expenses compared to Q1 2024; Additional Savings based on annualized additional savings.

U.S. AND REST OF WORLD DELIVER EFFICIENT REVENUE AND STRENGTHEN THE BRAND

United States

Implemented refined commercial strategy focused on payer coverage post-loss of exclusivity (LOE), which has provided significant, efficient and profitable VASCEPA revenue

Focused strategic execution has resulted in maintaining over 40% share of the IPE market and ongoing efficient cash flows

Significant experience and history through building up a large market in U.S.

- 28M prescriptions written in the U.S.
- 244K prescribers
- 2.4M patients on treatment

Rest of World

9 Rest of World partnerships focused on maximizing patient access to VASCEPA globally

Commercializing across 11 countries with an additional 8 markets which have regulatory submissions pending review/potential approval

Most partnerships remain in early commercialization stages poised to capture growth opportunity across CVRR

Partnerships continue to provide going forward Cash generation as VASCEPA/VAZKEPA continues to see growth globally across all partners in-market demand

- In aggregate, demand has grown 77% Q1'25 vs. Q1 '24



STRONG POSITION FOR THE FUTURE

VASCEPA/VAZKEPA Has Enormous Untapped Global Value

Significant potential to benefit millions of patients worldwide, backed by strong and validated science from REDUCE-IT, medical advocacy, growing list of country approvals, launches and partnerships

Strengthened Financial Foundation

Nearly \$300M cash, no debt, ~\$70M cost savings over next 12 months

Capturing Value From Multiple Revenue Streams

Cost efficient revenue generation from profitable U.S. business, new European partnership with Recordati and Rest of World partnerships

Exploring Strategic Actions to Maximize Shareholder Value

Ongoing work with Barclays as exclusive financial advisor to explore additional strategic opportunities to create shareholder value

